Healthcare Industry News: Barrett's esophagus
News Release - October 10, 2007
SpectraScience Receives Final European Certification
SAN DIEGO, Oct. 10 (HSMN NewsFeed) -- SpectraScience, Inc. (OTC Bulletin Board: SCIE ) announced today that it has received the final EC Marking Certification of the Company's quality system from the Notified Body G-MED. SpectraScience has been issued a certificate with reference to Annex II.3 of the European directive 93/42/EEC. In addition, ISO 9001:2000 and ISO 13485:2003 have been issued.Jim Hitchin the Company's CEO said, "This certification is an important validation of our manufacturing quality controls and procedures. In addition, we are now qualified to sell our products throughout the European Union, as well as many other countries around the world."
SpectraScience has developed a multi-patented and proprietary WavSTAT(TM) Optical Biopsy System that is used by physicians to diagnose tissue to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT(TM) System is currently approved by the FDA for use in detecting pre-cancer and cancer in the colon. A new application for detecting pre-cancers in the throat, sometimes called Barrett's esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
Source: SpectraScience
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
